Evidence map›Paper›PMID 34630432›Full record

ArticleFrontiers in immunology2021

Comprehensive Immune Profiling of a Kidney Transplant Recipient With Peri-Operative SARS-CoV-2 Infection: A Case Report.

Karen R Sherwood, David D M Nicholl, Franz Fenninger, Vivian Wu, Paaksum Wong, Vince Benedicto, Davide P Cina, Meng Wang, Taylor D Pobran, Mari L De Marco and 9 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Karen R SherwoodDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
David D M NichollDivision of Nephrology, University of British Columbia, Vancouver, BC, Canada.
Franz FenningerDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Vivian WuDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Paaksum WongDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Vince BenedictoBritish Columbia Provincial Immunology Laboratory, University of British Columbia, Vancouver, BC, Canada.
Davide P CinaDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Meng WangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Taylor D PobranDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Mari L De MarcoDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Anna Citlali MárquezBritish Columbia Center for Disease Control Public Health Laboratory, Provincial Health Services Authority, Vancouver, BC, Canada.
Agatha N JassemDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Inna SekirovDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Muhammad G MorshedDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Mohammad BardiDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Mypinder SekhonDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Paul KeownDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Matthew KadatzDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
James H LanDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To date there is limited data on the immune profile and outcomes of solid organ transplant recipients who encounter COVID-19 infection early post-transplant. Here we present a unique case where the kidney recipient's transplant surgery coincided with a positive SARS-CoV-2 test and the patient subsequently developed symptomatic COVID-19 perioperatively. We performed comprehensive immunological monitoring of cellular, proteomic, and serological changes during the first 4 critical months post-infection. We showed that continuation of basiliximab induction and maintenance of triple immunosuppression did not significantly impair the host's ability to mount a robust immune response against symptomatic COVID-19 infection diagnosed within the first week post-transplant.

Indexed as

Kidney TransplantationAdultBasiliximabCOVID-19Glomerulonephritis, IGAGraft RejectionHumansImmune ToleranceImmunityImmunosuppressive AgentsMalePerioperative PeriodSARS-CoV-2TranscriptomeBasiliximabImmunosuppressive AgentsCOVID-19immune responseimmunosuppressantsinduction therapytransplant

Identifiers

PMID34630432
PMCPMC8492986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.